Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.

This seminal review merits the Alzheimer Award for its exceptional scholarly contribution to tauopathy therapeutics. Dr. Sigurdsson masterfully synthesizes the clinical and preclinical landscape of tau immunotherapies – the dominant therapeutic class directly targeting tau. The work pinpoints the critical rationale: tau pathology's superior correlation with dementia severity versus amyloid-β, suggesting functional benefits might emerge later in disease progression. By evaluating epitope selection and antibody mechanisms across trials, this review provides an analysis essential for advancing viable tau-directed disease-modifying treatments.